High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

@article{WartelleBladou2006HighDD,
  title={High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.},
  author={Claire Wartelle-Bladou and Jean-Pierre Arpurt and Christophe Renou and Alexandre Pariente and Didier Pillon and Bernard Nalet and Magali Picon and Andr{\'e} Glibert and Michel Chousterman and Denis Grasset and Terrence J. Morin and Pierre Alain Bernard and Daniel Fischer and M. Pitrun Ramdani and Evelyne Lagier and Michel Rotily},
  journal={Gastroenterologie clinique et biologique},
  year={2006},
  volume={30 4},
  pages={
          525-32
        }
}
OBJECTIVES To evaluate in naive patients with chronic hepatitis C 1- the efficacy and safety of one month interferon alpha (IFN-alpha) induction regimen; 2- the potential virological benefit of a secondary adjunction of ribavirin among HCV RNA negative patients after 20 weeks of IFN therapy, with or without an initial 4-week IFN induction. MATERIAL AND METHODS 151 naive HCV-RNA positive patients presenting with biopsy- proven chronic hepatitis C and elevated ALT were randomised in a 2: 1… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

SJ Hadziyannis, H JrSette, +3 authors P Marcellin
  • Ann Intern Med
  • 2004
VIEW 1 EXCERPT